| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aso Hameed Hasan, Sankaranarayanan Murugesan, Syazwani Itri Amran, Subhash Chander, Mohammed M Alanazi, Taibi Ben Hadda, Sonam Shakya, Mohammad Rizki Fadhil Pratama, Basundhara Das, Subhrajit Biswas, Joazaizulfazli Jamali. Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation. Bioorganic chemistry. vol 119. 2021-12-31. PMID:34971946. |
a series of around eight novel chalcone based coumarin derivatives (23a-h) was designed, subjected to in-silico admet prediction, synthesized, characterized by ir, nmr, mass analytical techniques and evaluated as acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease (ad). |
2021-12-31 |
2023-08-13 |
Not clear |
| Luciana R Tallini, Angelo Carrasco, Karen Acosta León, Diego Vinueza, Jaume Bastida, Nora H Olea. Alkaloid Profiling and Cholinesterase Inhibitory Potential of Plants (Basel, Switzerland). vol 10. issue 12. 2021-12-28. PMID:34961157. |
the alkaloids obtained from the plant family amaryllidaceae have interesting structures and biological activities, such as acetylcholinesterase inhibition potential, which is one of the mechanisms used for the palliative treatment of alzheimer's disease symptoms. |
2021-12-28 |
2023-08-13 |
Not clear |
| Shiyang Zhou, Gangliang Huan. The biological activities of butyrylcholinesterase inhibitors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 146. 2021-12-25. PMID:34953393. |
acetylcholinesterase (ache) inhibitor is the first choice for the treatment of alzheimer's disease (ad), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. |
2021-12-25 |
2023-08-13 |
Not clear |
| Shiyang Zhou, Gangliang Huan. Synthesis and biological activities of butyrylcholinesterase inhibitors. Chemical biology & drug design. 2021-12-23. PMID:34942058. |
acetylcholinesterase (ache) inhibitor is the first choice for the treatment of alzheimer's disease (ad), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. |
2021-12-23 |
2023-08-13 |
Not clear |
| b' Derya Osmaniye, Asaf E Evren, Beg\\xc3\\xbcm N Sa\\xc4\\x9fl\\xc4\\xb1k, Serkan Levent, Yusuf \\xc3\\x96zkay, Zafer A Kaplanc\\xc4\\xb1kl\\xc4\\xb. Design, synthesis, biological activity, molecular docking, and molecular dynamics of novel benzimidazole derivatives as potential AChE/MAO-B dual inhibitors. Archiv der Pharmazie. 2021-12-21. PMID:34931332.' |
to develop new acetylcholinesterase (ache)-monoamine oxidase-b (mao-b) dual inhibitors against alzheimer's disease, the benzimidazole ring, which has a propargyl side chain with previously proven selective mao-b inhibitory activity, was used as the main structure. |
2021-12-21 |
2023-08-13 |
Not clear |
| Donald E Moss, Ruth G Pere. Anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's disease: Nexus of cholinergic and nerve growth factor dysfunction. Current Alzheimer research. 2021-12-16. PMID:34911424. |
anti-neurodegenerative benefits of acetylcholinesterase inhibitors in alzheimer's disease: nexus of cholinergic and nerve growth factor dysfunction. |
2021-12-16 |
2023-08-13 |
Not clear |
| Qiannan Zhu, Min Lin, Wanying Zhuo, Yunzhi L. Chemical Constituents from the Wild Molecules (Basel, Switzerland). vol 26. issue 23. 2021-12-10. PMID:34885880. |
chemical constituents from the wild screening the lead compounds which could interact both with pas and cas of acetylcholinesterase (ache) is an important trend in finding innovative drugs for alzheimer's disease (ad). |
2021-12-10 |
2023-08-13 |
Not clear |
| Vincentsia Vienna Vanessa, Siau Hui Ma. Xanthone: Potential Acetylcholinesterase Inhibitor for Alzheimer's Disease Treatment. Mini reviews in medicinal chemistry. vol 21. issue 17. 2021-12-07. PMID:33583373. |
xanthone: potential acetylcholinesterase inhibitor for alzheimer's disease treatment. |
2021-12-07 |
2023-08-13 |
Not clear |
| Flávia Suelen de Oliveira Pereira, Flavio Augusto Rocha Barbosa, Rômulo Farias Santos Canto, Cristiane Lucchese, Simone Pinton, Antônio Luiz Braga, Juliano Braun de Azeredo, Caroline Brandão Quines, Daiana Silva Ávil. Dihydropyrimidinone-derived selenoesters efficacy and safety in an in vivo model of Aβ aggregation. Neurotoxicology. vol 88. 2021-12-02. PMID:34718060. |
in a previous in vitro study, dihydropyrimidinone-derived selenoesteres demonstrated antioxidant properties, metal chelators and inhibitory acetylcholinesterase (ache) activity, making these compounds promising candidates for alzheimer's disease (ad) treatment. |
2021-12-02 |
2023-08-13 |
caenorhabditis_elegans |
| Marta Pérez-Gómez Moreta, Natalia Burgos-Alonso, María Torrecilla, José Marco-Contelles, Cristina Bruzos-Cidó. Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. Review of Reviews. Biomedicines. vol 9. issue 11. 2021-11-30. PMID:34829917. |
efficacy of acetylcholinesterase inhibitors on cognitive function in alzheimer's disease. |
2021-11-30 |
2023-08-13 |
Not clear |
| Mohammad Zamanian, Gholamreza Bazmandegan, Antoni Sureda, Eduardo Sobarzo-Sanchez, Hasan Yousefi-Manesh, Samira Shirooi. The Protective Roles and Molecular Mechanisms of Troxerutin (Vitamin P4) for the Treatment of Chronic Diseases: A Mechanistic Review. Current neuropharmacology. vol 19. issue 1. 2021-11-25. PMID:32386493. |
trx also reduces acetylcholinesterase activity and upregulates phosphoinositide 3- kinase/akt signaling pathway in alzheimer's disease models. |
2021-11-25 |
2023-08-13 |
Not clear |
| Alastair J H Brown, Sophie J Bradley, Fiona H Marshall, Giles A Brown, Kirstie A Bennett, Jason Brown, Julie E Cansfield, David M Cross, Chris de Graaf, Brian D Hudson, Louis Dwomoh, João M Dias, James C Errey, Edward Hurrell, Jan Liptrot, Giulio Mattedi, Colin Molloy, Pradeep J Nathan, Krzysztof Okrasa, Greg Osborne, Jayesh C Patel, Mark Pickworth, Nathan Robertson, Shahram Shahabi, Christoffer Bundgaard, Keith Phillips, Lisa M Broad, Anushka V Goonawardena, Stephen R Morairty, Michael Browning, Francesca Perini, Gerard R Dawson, John F W Deakin, Robert T Smith, Patrick M Sexton, Julie Warneck, Mary Vinson, Tim Tasker, Benjamin G Tehan, Barry Teobald, Arthur Christopoulos, Christopher J Langmead, Ali Jazayeri, Robert M Cooke, Prakash Rucktooa, Miles S Congreve, Malcolm Weir, Andrew B Tobi. From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. Cell. vol 184. issue 24. 2021-11-25. PMID:34822784. |
current therapies for alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. |
2021-11-25 |
2023-08-13 |
Not clear |
| Muhammad Shahid Nadeem, Jalaluddin Azam Khan, Umer Rashi. Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies. International journal of biological macromolecules. vol 193. issue Pt A. 2021-11-24. PMID:34687762. |
for the potential therapy of alzheimer's disease (ad), cholinesterases (che) and monoamine oxidase (mao) are key enzymes that regulate the level of acetylcholinesterase (ache)/butyrylcholinesterase (bche) and monoamines. |
2021-11-24 |
2023-08-13 |
mouse |
| Bhuvaneswari Sivaraman, Vijaykumar R, Bala Aakash Velmurugan, Ramalakshmi Nataraja. Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease. CNS & neurological disorders drug targets. 2021-11-23. PMID:34602041. |
acetylcholinesterase enzyme inhibitor molecules with therapeutic potential for alzheimer's disease. |
2021-11-23 |
2023-08-13 |
Not clear |
| Fauzia Parween, Md Summon Hossain, Kshetra Pal Singh, Rinkoo Devi Gupt. Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease. PloS one. vol 16. issue 10. 2021-11-23. PMID:34714861. |
association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against alzheimer's disease. |
2021-11-23 |
2023-08-13 |
human |
| Fauzia Parween, Md Summon Hossain, Kshetra Pal Singh, Rinkoo Devi Gupt. Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease. PloS one. vol 16. issue 10. 2021-11-23. PMID:34714861. |
since cholinergic deficiency is closely linked with alzheimer's disease (ad) progression, acetylcholinesterase inhibitors (acheis) are the treatment of choice for patients with ad. |
2021-11-23 |
2023-08-13 |
human |
| Fanny C F Ip, Guangmiao Fu, Fengzhi Yang, Fangyuan Kang, Peiran Sun, Choi Ying Ling, Kit Cheung, Fangzhou Xie, Yueqing Hu, Lei Fu, Nancy Y I. A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice. European journal of medicinal chemistry. vol 226. 2021-11-22. PMID:34530383. |
acetylcholinesterase (ache) inhibitors have been used to improve cholinergic transmission in the brain for two decades and have proven effective for alleviating symptoms in the early stages of alzheimer's disease. |
2021-11-22 |
2023-08-13 |
mouse |
| Maria I Lazarova, Daniela S Tsekova, Lyubka P Tancheva, Kiril T Kirilov, Diamara N Uzunova, Lyubomir T Vezenkov, Elina R Tsvetanova, Albena V Alexandrova, Almira P Georgieva, Petja T Gavrilova, Stela T Dragomanova, Maria G Papazova, Yordan S Handzhiyski, Reni E Kalfi. New Galantamine Derivatives with Inhibitory Effect on Acetylcholinesterase Activity. Journal of Alzheimer's disease : JAD. vol 83. issue 3. 2021-11-19. PMID:34420968. |
inhibitors of acetylcholinesterase (ache) are used to treat many disorders, among which are neurodegenerative upsets, like alzheimer's disease (ad). |
2021-11-19 |
2023-08-13 |
Not clear |
| Maria Devita, Fabio Masina, Daniela Mapelli, Pasquale Anselmi, Giuseppe Sergi, Alessandra Coi. Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer's disease. Aging clinical and experimental research. vol 33. issue 11. 2021-11-18. PMID:33763839. |
acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild alzheimer's disease. |
2021-11-18 |
2023-08-13 |
Not clear |
| Maria Devita, Fabio Masina, Daniela Mapelli, Pasquale Anselmi, Giuseppe Sergi, Alessandra Coi. Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer's disease. Aging clinical and experimental research. vol 33. issue 11. 2021-11-18. PMID:33763839. |
acetylcholinesterase inhibitors (achei) and cognitive stimulation (cs) are the standard pharmacological and non-pharmacological treatments for alzheimer's disease (ad). |
2021-11-18 |
2023-08-13 |
Not clear |